Paper Details

  1. Home
  2. Paper Details

Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.

Author: BelliardSimon, Berrebi-BertrandIsabelle, FinanceOlivier, GiretMartin, KriefStéphane, LecomteJeanne-Marie, LigneauXavier, NagmarIsabelle, PerrinDavid, RobertPhilippe, SchwartzJean-Charles, UguenMarilyne

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pitolisant, a selective H3 receptor antagonist/inverse agonist, demonstrated different biochemical, neurochemical, and behavioral profiles compared to amphetamine, modafinil, and solriamfetol, making it a differentiated therapeutic option for excessive daytime sleepiness.
Paper Details　
Original Abstract of the Article :
Several therapeutic options are currently available to treat excessive daytime sleepiness (EDS) in patients suffering from narcolepsy or obstructive sleep apnea. However, there are no comparisons between the various wake-promoting agents in terms of mechanism of action, efficacy, or safety. The goal...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381683/

データ提供：米国国立医学図書館（NLM）

Pitolisant: A Wake-Promoting Agent Without the Jitters

Excessive daytime sleepiness (EDS) is a debilitating symptom that can significantly impact daily life. This study compares pitolisant, a novel wake-promoting agent, to other existing treatments for EDS, including amphetamine, modafinil, and solriamfetol. The researchers investigated the pharmacological mechanisms of action, efficacy, and safety profiles of these drugs, focusing on their effects on neurotransmitters and behavior.

Pitolisant's Unique Profile

The study revealed that pitolisant, a selective histamine H3 receptor antagonist/inverse agonist, promotes wakefulness without exhibiting the psychostimulant properties associated with other wake-promoting agents. The researchers found that pitolisant did not affect dopamine levels or produce hyperlocomotion, behavioral sensitization, or hypophagia, which are common side effects of psychostimulants. This suggests that pitolisant may offer a safer and more tolerable alternative for treating EDS.

A Clear Path: Navigating the Landscape of Wake-Promoting Agents

This preclinical study provides valuable insights into the unique profile of pitolisant as a wake-promoting agent. It suggests that pitolisant may offer a safer and more effective treatment option for EDS compared to traditional psychostimulants. It's like finding a clear path through a desert, offering a safer and more efficient route to reach your destination.

Dr. Camel's Conclusion

This preclinical study demonstrates the unique pharmacological profile of pitolisant, a wake-promoting agent that lacks the psychostimulant properties of other medications used for EDS. The findings suggest that pitolisant may be a safer and more tolerable alternative for patients with EDS. This research offers a promising new option for managing EDS, highlighting the importance of exploring alternative treatments with improved safety profiles.

Date :
  1. Date Completed 2022-02-14
  2. Date Revised 2022-02-14
Further Info :

Pubmed ID

34423920

DOI: Digital Object Identifier

PMC8381683

Related Literature

Article Analysis
・Effects of solriamfetol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.